How Do Psychedelics Reduce Fear of Death?
The paper argues that psychedelic experiences reduce fear of death primarily by inducing non‑physicalist metaphysical belief change rather than by purely psychological or physiological mechanisms. This finding supports the REBUS model of psychedelic therapy and challenges "neuroexistentialist" aims to naturalise spirituality, since the benefits seem to depend on persuading people away from a broadly naturalistic worldview.
Abstract
Increasing evidence suggests that psychedelic experiences, undergone in controlled conditions, can have various durable psychological benefits. One such benefit is reductions in fear of death, which have been attested in both psychiatric patients and healthy people. This paper addresses the question: how, exactly, do psychedelic experiences reduce fear of death? It argues, against some prominent proposals, that they do so mainly by promoting non-physicalist metaphysical beliefs. This conclusion has implications for two broader debates: one about the mechanisms of psychedelic therapy, and one about the potential non-medical uses of psychedelics for the alleviation of existential angst in psychiatrically healthy people. On the first count, the paper argues that the role of metaphysical belief change in fear of death supports the “Relaxed Beliefs Under Psychedelics” (REBUS) model of psychedelic therapy over alternative accounts. On the second count, the paper argues that the role of metaphysical belief change undermines the proposed use of psychedelics in the “neuroexistentialist” project of naturalizing spirituality. The best available evidence suggests that when psychedelic experiences reduce existential angst and restore a sense of meaning in life, they do so primarily by persuading people of the falsity of a broadly naturalistic worldview, and thus do not help reconcile people to the truth of such a worldview.
Research Summary of 'How Do Psychedelics Reduce Fear of Death?'
Introduction
The paper frames a central question: by what psychological mechanism do classic (serotonin-2A agonist) psychedelic experiences reduce fear of death? It begins by noting accumulating clinical and anecdotal evidence that a single moderate-to-high dose can produce durable reductions in existential dread and death anxiety in both terminally ill patients and some healthy volunteers. The introduction situates this question within two broader debates: mechanisms of psychedelic therapy (notably the contrast between metaphysical-belief-change accounts and self-representation accounts) and the prospect that psychedelics might serve non‑medical, existential purposes such as a ‘‘naturalistic’’ spirituality. Letheby states the paper’s aim as an evidential and conceptual inquiry into whether reductions in fear of death are primarily driven by changes in metaphysical beliefs (the Metaphysical Belief Theory) or by other psychological processes such as alterations in self-representation. He previews a tentative conclusion: available evidence favours a prominent role for non‑physicalist metaphysical belief change in reducing death anxiety, and that this conclusion bears on the broader REBUS (Relaxed Beliefs Under Psychedelics) model and on proposals to use psychedelics to reconcile naturalistic worldviews with existential peace.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Author
- APA Citation
Letheby, C. (2024). How Do Psychedelics Reduce Fear of Death?. Neuroethics, 17(2). https://doi.org/10.1007/s12152-024-09564-3
References (21)
Papers cited by this study that are also in Blossom
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Gukasyan, N., Nayak, S. · Preprints (2020)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Moreton, S. G., Arena, A. F., Foy, Y. et al. · Death Studies (2023)
Show all 21 referencesShow fewer
Moreton, S. G., Szalla, L., Menzies, R. E. et al. · Psychopharmacology (2019)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Swee, M. B., Nayak, S., Hurwitz, E. et al. · PLOS ONE (2022)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Timmermann, C., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Cited By (1)
Papers in Blossom that reference this study
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.